Centre Paul Strauss
Clinical trials sponsored by Centre Paul Strauss, explained in plain language.
-
Could a saffron-derived compound boost radiation for sarcoma?
Disease control Not yet recruitingThis phase 2 trial tests whether adding a drug called liposomal transcrocetin (L-TC) to short-course radiation before surgery can kill more cancer cells in people with soft-tissue sarcoma. About 42 adults with localized or locally advanced sarcoma will be randomly assigned to rec…
Phase: PHASE2 • Sponsor: Centre Paul Strauss • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Fewer days of radiation may control brain tumors just as well
Disease control Not yet recruitingThis phase 3 trial compares two radiation schedules for people with 1 to 5 brain metastases from cancers like melanoma, kidney, or sarcoma. One group gets radiation on days 1, 3, and 5; the other on days 1, 2, and 3. The goal is to see if the shorter schedule controls tumor growt…
Phase: PHASE3 • Sponsor: Centre Paul Strauss • Aim: Disease control
Last updated Jun 26, 2026 16:49 UTC
-
Can light be the new shield against radiation mouth sores?
Prevention Not yet recruitingThis pilot study tests two light therapy devices—one placed inside the mouth and one outside—to prevent and treat painful mouth sores caused by radiation therapy. Sixty adults with oral cavity or oropharynx cancer will receive light sessions twice a week for prevention, then thre…
Phase: NA • Sponsor: Centre Paul Strauss • Aim: Prevention
Last updated Jun 27, 2026 13:02 UTC
-
Brain scans reveal hidden impact of deadly tumors on thinking
Knowledge-focused Not yet recruitingThis study looks at how glioblastoma, a serious brain cancer, changes the way brain cells communicate and use energy. Researchers will use special PET and MRI scans to map these changes in 80 adults before and after surgery. The goal is to link scan results with thinking and memo…
Phase: NA • Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Can a smarter scan spot breast cancer treatment failure faster?
Knowledge-focused Not yet recruitingThis study compares two types of scans—standard CT and bone scans versus PET-CT—to see which better evaluates how well the drug trastuzumab deruxtecan (T-DXd) works in people with HER2 low metastatic breast cancer. About 262 participants will be split into two groups and scanned …
Phase: NA • Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:12 UTC